Nordic Aqua Partners A/S NOAP
Oslo Børs · Consumer Defensive · Farm Products
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for Nordic Aqua Partners
| EUR million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 0 | 0 | 6 | 13 |
| EBITDA | −5 | −6 | −13 | −11 |
| Net income | −5 | −8 | −17 | −16 |
| Balance sheet | ||||
| Equity | 48 | 73 | 87 | 89 |
| Total debt | 0 | 25 | 63 | 63 |
| Cash | 13 | 22 | 18 | 12 |
| Net debt | −13 | 2 | 45 | 51 |
| Ratios and per share | ||||
| EBITDA margin | – | – | −206.0% | −86.0% |
| Profit margin | – | – | −268.2% | −126.7% |
| Return on equity | −11.3% | −11.2% | −20.1% | −18.3% |
| Earnings/share (EUR) | −0.51 | −0.49 | −0.82 | −0.77 |
| Book value/share (EUR) | 4.52 | 4.32 | 4.10 | 4.20 |
| Shares outstanding (M) | 11 | 17 | 21 | 21 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Quarterly figures from the reports
BetaFrom the company's own reports: 12 reports read by AI, every figure checked against the report's page and arithmetic.
Source: the Q2 2026 report, page 21, published 2026-08-26.
| Quarter | Revenue | Operating profit | Profit | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q2 2026 | 9 | −5 | −3 | −0.16 | … | Q2 2026, p. 21 |
| Q1 2026 | 6 | 4 | 2 | 0.10 | … | Q1 2026, p. 20 |
| Q4 2025 | 2 | −2 | 0 | 0.02 | … | Q4 2025 and FY 2025, p. 21 |
| Q3 2025 | 4 | −2 | −2 | −0.11 | … | Q3 2025, p. 21 |
| Q2 2025 | 5 | −5 | −10 | −0.48 | … | Q2 2025, p. 21 |
| Q1 2025 | 2 | −2 | −4 | −0.20 | … | Q1 2025, p. 20 |
| Q4 2024 | 2 | −6 | −2 | −0.06 | … | Q4 2024, p. 22 |
| Q3 2024 | 0 | −12 | −14 | −0.85 | … | Q3 2024, p. 21 |
| Q2 2024 | 5 | −2 | −2 | −0.10 | … | Q2 2025, p. 21 |
| Q1 2024 | 0 | 0 | 0 | 0.00 | … | Q1 2025, p. 20 |
| Q4 2023 | 0 | −2 | −4 | −0.27 | … | Q4 2023, p. 29 |
| Q3 2023 | 0 | −1 | 0 | 0.04 | … | Q3 2023, p. 23 |
Amounts in EUR million, EPS in EUR. Each quarter as first reported, as a backtest would have seen it. Adjusted EPS (without one-off items) is shown once the one-off items have been checked against the companies' own adjusted figures.
One-off items in the reports
- 2026-06-30 Fair value adjustment of biological assets (excluded from Operating EBIT and Operating EBITDA): −4.2 EUR million (Q2 2026, p. 21)
- 2026-03-31 Fair value adjustment of biological assets (biomass), excluded from Operating EBIT: +4.2 EUR million (Q1 2026, p. 20)
- 2025-12-31 Fair value adjustment of biological assets, gain in Q4 2025, excluded from Operating EBIT: +2.0 EUR million (Q4 2025 and FY 2025, p. 21)
- 2025-09-30 Fair value adjustments of biological assets, excluded from Operating EBIT: +2.3 EUR million (Q3 2025, p. 21)
- 2025-06-30 Fair value adjustments of biological assets (Q2 2025): −2.1 EUR million (Q2 2025, p. 21)
- 2025-03-31 Fair value adjustment of biological assets, excluded from Operating EBIT: −0.5 EUR million (Q1 2025, p. 20)
- 2024-12-31 Fair value of biological assets, excluded from Operating EBIT: −0.5 EUR million (Q4 2024, p. 29)
- 2024-09-30 Fair value of biological assets, excluded from Operating EBIT (Q3 2024): −0.3 EUR million (Q3 2024, p. 21)
Found by AI and still being validated: hover for the report's own words.
Sign in for free to open each report on the page a figure comes from.
Extracted by an AI model from the reports and can be wrong. Not investment advice.
Key figures
| P/E | – |
| P/B | 2.1 |
| EV / EBITDA | – |
| Net debt / EBITDA | – |
| Return on equity | −18.3% |
| Profit margin | −126.7% |
| Beta 1Y | −0.03 |
| Revenue growth 1Y | +98.3% |
| ROE avg. 3Y | −16.5% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (NOK)
No dividends paid in the last five years.
Not investment advice. Figures may contain errors from the data source.